OTLC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OTLC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Oncotelic Therapeutics's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($0.18 Mil) to Sep. 2023 ($0.27 Mil) but then stayed the same from Sep. 2023 ($0.27 Mil) to Dec. 2023 ($0.17 Mil).
Oncotelic Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($0.57 Mil) to Dec. 2022 ($0.24 Mil) and declined from Dec. 2022 ($0.24 Mil) to Dec. 2023 ($0.17 Mil).
The historical data trend for Oncotelic Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash, Cash Equivalents, Marketable Securities | Get a 7-Day Free Trial | 0.08 | 0.47 | 0.57 | 0.24 | 0.17 |
Oncotelic Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash, Cash Equivalents, Marketable Securities | Get a 7-Day Free Trial | 0.24 | 0.19 | 0.18 | 0.27 | 0.17 |
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Oncotelic Therapeutics (OTCPK:OTLC) Cash, Cash Equivalents, Marketable Securities Explanation
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Thank you for viewing the detailed overview of Oncotelic Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Vuong Trieu | officer: CHIEF EXECUTIVE OFFICER | 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301 |
Saran Saund | officer: CHIEF BUSINESS OFFICER | C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301 |
Amit B. Shah | officer: CHIEF FINANCIAL OFFICER | 10 AGUILA, ALISO VIEJO CA 92656 |
Chulho Park | officer: CHIEF TECHNOLOGY OFFICER | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Maida Anthony E Iii | director | 157 TECHNOLOGY DR, IRVINE CA 92618 |
Steven W King | director | |
David Diamond | director | 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301 |
Fatih Uckun | 10 percent owner, officer: Chief Medical Officer | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Chao Hsiao | 10 percent owner | 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080 |
Larn Hwang | 10 percent owner | C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748 |
Donald Rogers Reynolds | director | C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607 |
Sandage Bobby W Phd | director | C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173 |
Simon Pedder | director | 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203 |
Matthew M Loar | officer: Chief Financial Officer | 505 PENOBSCOT DR, REDWOOD CITY CA 94063 |
Pamela Ha | officer: Controller | 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-07-2022
By Tiesvg Tiesvg • 12-28-2022
By GuruFocusNews GuruFocusNews • 07-04-2022
By Stock market mentor Stock market mentor • 01-25-2023
By Stock market mentor Stock market mentor • 01-17-2023
By sperokesalga sperokesalga • 04-24-2023
By sperokesalga sperokesalga • 03-20-2023
By Stock market mentor Stock market mentor • 02-06-2023
By Marketwired • 08-23-2023
By sperokesalga sperokesalga • 04-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.